Mass General - Division of Clinical Research

Cohort 1 - Alive Individuals - Men or women 18 years of age or the age of majority for their residential state of the United States, or older, at the time of consent. - Histologically or cytologically confirmed advanced stage IIIB-IIIC not amenable to curative approach multi-modality (e.g., chemoradiation and/or surgery) treatment, or stage IV non-small cell lung cancer (NSCLC) - Demonstration of having advanced ALK+ NSCLC, as assessed by fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), next-generation sequencing (NGS) or circulating tumor DNA analysis (ctDNA). For ALK FISH, fusions must have been detected in at least 15% of tumor cells. - Willingness to provide clinical and medical information to the study team as required. - Willingness to provide archival tumor tissue, if available. Patients may enroll even if no tumor tissue is available. - Ability to read, write and communicate in English. - Ability to sign a web-based informed consent form. Cohort 2 - Deceased Individuals - Deceased individuals diagnosed with advanced ALK+ lung cancer at age 18 years or older may be studied on a case by case basis. Inclusion will require availability of adequate archived tissue and release of tissue and records by next of kin, if available.

• Participants who are unwilling to provide informed consent. - Participants who are younger than 18 years of age. - Participants who are unable to comply with the study procedures. - Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements. - Participants who have previously enrolled to the study.